Product news

Share this article:

Genzyme announced the US launch of phosphate binder Renvela (sevelamer carbonate) for dialysis patients. Renvela is a next-generation version of Renagel (sevelamer hydrochloride). It is a calcium-free, metal-free, non-absorbed phosphate binder and is available in the US as 800 mg tablets.

Onset Therapeutics, a specialty pharmaceutical company that focuses on the development and commercialization of innovative treatments for skin and skin-related disorders, has launched Anestafoam, a novel topical foam formulation containing lidocaine 4%.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions